Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Preliminary data from a phase III study indicate that MedImmune's nasal-spray influenza vaccine FluMist, was significantly better at protecting against flu than conventional flu shots.
Subscribe to our email newsletter
MedImmune’s nasal spray CAIV-T produced a reduction of 55% in influenza illness caused by any influenza strain compared to a standard injectable flu vaccine. 8.6% of the participants in the study receiving injectable influenza vaccine became ill with the flu, compared to 3.9% of those using the nasal spray.
CAIV-T is an improved formulation of FluMist, a frozen vaccine currently approved to prevent influenza in healthy children and adolescents, 5 to 17 years of age, and healthy adults, 18 to 49 years of age.
“This pivotal trial is the third phase III trial of CAIV-T to show statistically significant reductions in influenza disease compared to the injectible influenza vaccine. Collectively, these data suggest better efficacy against matched and mismatched strains and against both A and B strains,” said David Mott, president and CEO.
The study enrolled 8,492 children and was conducted at 249 sites in 16 countries in North America, Europe and Asia.